title: Clinical pharmacokinetics and effects of vincristine sulfate in dogs with transmissible venereal tumor (TVT).
abstract: This study was conducted to evaluate the pharmacokinetic characteristics of vincristine and their correlation with its clinical effects in dogs with transmissible venereal tumor (TVT). Dogs with TVT were intravenously administered vincristine sulfate at a dose of 0.7 mg/m(2) of body surface area. Blood samples were collected starting from 5 min to 48 hr after drug administration. The plasma concentration of vincristine was determined using liquid chromatography-tandem mass spectrometry (LC-MS/MS). The pharmacokinetic parameters of vincristine were characterized using a two-compartmental pharmacokinetic model. The volume of distribution, distribution half-life, elimination half-life and plasma clearance were 0.660 ± 0.210 l/kg, 21.5 ± 6.90 min, 47.6 ± 14.2 min and 0.010 ± 0.001 l/min/kg, respectively. Tumor regression was determined at weekly interval by a physical examination and histopathological analysis. In our study, three to eight administrations of vincristine at a dose of 0.7 mg/m(2) were able to induce a complete tumor regression without any evidence of gross lesion of disease. Therefore, this investigation provides the pharmacokinetic characteristics of vincristine in dogs with TVT, which may be used as an integration tool to gain a better understanding of the disposition properties of the drug and the correlation of these properties with the drug's clinical effects. In addition, we validated the LC-MS/MS method and found that it is suitable for the pharmacokinetic study of vincristine in dog plasma.
authors: Department of Pharmacology, Faculty of Veterinary Medicine, Kasetsart University Bangkok 10900, Thailand.
authors: Supannika
authors: S
authors: Hantrakul
authors: Narumol
authors: N
authors: Klangkaew
authors: Sunee
authors: S
authors: Kunakornsawat
authors: Tawewan
authors: T
authors: Tansatit
authors: Ammart
authors: A
authors: Poapolathep
authors: Susumu
authors: S
authors: Kumagai
authors: Saranya
authors: S
authors: Poapolathep
mesh_terms: D061605:Administration, Intravenous; D000818:Animals; D002853:Chromatography, Liquid / Q000379:methods / Q000662:veterinary*; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D006207:Half-Life; D008954:Models, Biological; D053719:Tandem Mass Spectrometry / Q000379:methods / Q000662:veterinary*; D014685:Venereal Tumors, Veterinary / Q000188:drug therapy*; D014750:Vincristine / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use
chemical_list: D014750:Vincristine
references: Vet Res Commun. 2000 Dec;24(8):545-56
references: 11305746
references: Cancer Chemother Pharmacol. 2014 Mar;73(3):459-66
references: 24362508
references: J Pharmacol Exp Ther. 2001 Sep;298(3):1206-12
references: 11504822
references: J Vet Med A Physiol Pathol Clin Med. 2001 Sep;48(7):391-400
references: 11599677
references: Biochem Biophys Res Commun. 1972 May 26;47(4):685-91
references: 5026289
references: Cancer Res. 1976 Oct;36(10):3684-9
references: 953993
references: Cancer Res. 1981 Apr;41(4):1466-8
references: 6260340
references: J Vet Intern Med. 1990 May-Jun;4(3):144-7
references: 2366223
references: J Am Vet Med Assoc. 1990 Aug 15;197(4):504-6
references: 2211297
references: Vet Res Commun. 1996;20(1):71-81
references: 8693703
references: J Pharm Biomed Anal. 1997 Dec;16(4):675-87
references: 9502163
references: J Am Anim Hosp Assoc. 1998 Nov-Dec;34(6):463-70
references: 9826280
references: Crit Rev Oncol Hematol. 1999 Feb;29(3):267-87
references: 10226730
references: J Vet Med A Physiol Pathol Clin Med. 2005 Sep;52(7):366-70
references: 16109105
references: Cancer Chemother Pharmacol. 2006 Apr;57(4):458-64
references: 16187113
references: J Pharm Biomed Anal. 2006 May 3;41(2):540-3
references: 16414232
references: J Mass Spectrom. 2007 Jun;42(6):761-70
references: 17511020
references: Rapid Commun Mass Spectrom. 2008;22(4):519-25
references: 18228243
references: Br J Haematol. 2008 Aug;142(4):616-21
references: 18537965
references: J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Feb 1;878(3-4):423-7
references: 20042378
references: J Chromatogr A. 2013 Feb 1;1275:61-9
references: 23294995
references: PLoS One. 2013;8(6):e65133
references: 23762298
references: Ther Drug Monit. 2001 Aug;23(4):406-9
references: 11477324